Marshall
Showing 1–2 of 2 transcripts.
- Goldman Sachs17 min
From “The Way Forward" Conference: Dr. Leonard S. Schleifer, Co-Founder, Regeneron Pharmaceuticals
Dr. Leonard S. Schleifer, Marshall
Regeneron, led by CEO Dr. Leonard Schleifer and co-founder George Yancopoulos, accelerated antibody therapy development to five months for Ebola and a new viral threat by utilizing a proprietary mouse platform and a dual-antibody cocktail designed to prevent viral escape mutants. The company targets three distinct patient populations with the goal of reducing viral duration and preventing severe progression, prioritizing high-impact intervention over mass vaccination. This strategy leverages converged wet sciences and rapid sequencing technologies to validate the cocktail's efficacy against variants within hours, with critical clinical data anticipated in late summer.
- Goldman Sachs14 min
From “The Way Forward" Conference: Esther Krofah, Executive Director, FasterCures
Faster Cures currently monitors over 200 SARS-CoV-2 therapeutic candidates and 163 vaccine prospects, with the majority of treatments in Phase 2 or 3 testing and key programs like Moderna's mRNA vaccine and the Oxford/AstraZeneca project advancing rapidly. While early data supports Remdesivir and convalescent plasma as partial solutions, experts anticipate effective cures will likely emerge from combination therapies and require Emergency Use Authorizations between fall 2020 and early 2021. Vaccine availability for frontline workers is targeted for late 2020, though the accelerated 12-to-18-month timeline relies on aggressive manufacturing scaling and successful clinical data readouts expected by autumn.